Polish President: the issue of providing fighters to Ukraine should be jointly decided by NATO countries

Synthetic Biology: Who Will Emerge as the Winner?

The 21st century is the century of biology. Synthetic biology is believed to be a ‘World Changing’ industry. But the potential risks like cost control and commercialization pathways are fatefully tied to the ups and downs of countless investment decisions and the destiny of the many new start-ups getting involved. We look forward to seeing an emerging ‘giant’ on the horizon of this exciting industry.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.

Bloomage: Injecting Biotechnology into Beauty Care

Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100.